anti-cd3 conjugated to recombinant ricin a chain
mAbexperimentalADC
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2010 (NCT00640497)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- Ricin A chain
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-cd3 conjugated to recombinant ricin a chain
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00640497 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2010 | Henogen, Radboud University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Henogen | For profit | 1 | 1 | 1 | 2010 |
| Radboud University | Academic/Hospital | 1 | 0 | 1 | 2010 |
2 organizations
Page 1 / 1